Light chain amyloidosis - current findings and future prospects
- PMID: 19538145
- PMCID: PMC3898330
- DOI: 10.2174/138920309789351949
Light chain amyloidosis - current findings and future prospects
Abstract
Systemic light chain amyloidosis (AL) is one of several protein misfolding diseases and is characterized by extracellular deposition of immunoglobulin light chains in the form of amyloid fibrils [1]. Immunoglobulin (Ig) proteins consist of two light chains (LCs) and two heavy chains (HCs) that ordinarily form a heterotetramer which is secreted by a plasma cell. In AL, however, a monoclonal plasma cell population produces an abundance of a pathogenic LC protein. In this case, not all of the LCs pair with the HCs, and free LCs are secreted into circulation. The LC-HC dimer is very stable, and losing this interaction may result in an unstable LC protein [2]. Additionally, somatic mutations are thought to cause amyloidogenic proteins to be less stable compared to non-amyloidogenic proteins [3-5], leading to protein misfolding and amyloid fibril formation. The amyloid fibrils cause tissue damage and cell death, leading to patient death within 12-18 months if left untreated [6]. Current therapies are harsh and not curative, including chemotherapy and autologous stem cell transplants. Studies of protein pathogenesis and fibril formation mechanisms may lead to better therapies with an improved outlook for patient survival. Much has been done to determine the molecular factors that make a particular LC protein amyloidogenic and to elucidate the mechanism of amyloid fibril formation. Anthony Fink's work, particularly with discerning the role of intermediates in the fibril formation pathway, has made a remarkable impact in the field of amyloidosis research. This review provides a general overview of the current state of AL research and also attempts to capture the most recent ideas and knowledge generated from the Fink laboratory.
Figures


Similar articles
-
Fatal amyloid formation in a patient's antibody light chain is caused by a single point mutation.Elife. 2020 Mar 10;9:e52300. doi: 10.7554/eLife.52300. Elife. 2020. PMID: 32151314 Free PMC article.
-
Mutations in specific structural regions of immunoglobulin light chains are associated with free light chain levels in patients with AL amyloidosis.PLoS One. 2009;4(4):e5169. doi: 10.1371/journal.pone.0005169. Epub 2009 Apr 13. PLoS One. 2009. PMID: 19365555 Free PMC article.
-
Differential recruitment efficacy of patient-derived amyloidogenic and myeloma light chain proteins by synthetic fibrils-A metric for predicting amyloid propensity.PLoS One. 2017 Mar 28;12(3):e0174152. doi: 10.1371/journal.pone.0174152. eCollection 2017. PLoS One. 2017. PMID: 28350808 Free PMC article.
-
Review: immunoglobulin light chain amyloidosis--the archetype of structural and pathogenic variability.J Struct Biol. 2000 Jun;130(2-3):280-9. doi: 10.1006/jsbi.2000.4248. J Struct Biol. 2000. PMID: 10940232 Review.
-
Immunoglobulin light chain amyloid aggregation.Chem Commun (Camb). 2018 Sep 20;54(76):10664-10674. doi: 10.1039/c8cc04396e. Chem Commun (Camb). 2018. PMID: 30087961 Free PMC article. Review.
Cited by
-
Cell Damage in Light Chain Amyloidosis: FIBRIL INTERNALIZATION, TOXICITY AND CELL-MEDIATED SEEDING.J Biol Chem. 2016 Sep 16;291(38):19813-25. doi: 10.1074/jbc.M116.736736. Epub 2016 Jul 26. J Biol Chem. 2016. PMID: 27462073 Free PMC article.
-
Identification of two principal amyloid-driving segments in variable domains of Ig light chains in systemic light-chain amyloidosis.J Biol Chem. 2018 Dec 21;293(51):19659-19671. doi: 10.1074/jbc.RA118.004142. Epub 2018 Oct 24. J Biol Chem. 2018. PMID: 30355736 Free PMC article.
-
IgG Fab fragments forming bivalent complexes by a conformational mechanism that is reversible by osmolytes.J Biol Chem. 2012 Dec 14;287(51):42936-50. doi: 10.1074/jbc.M112.410217. Epub 2012 Oct 29. J Biol Chem. 2012. PMID: 23109335 Free PMC article.
-
A single mutation promotes amyloidogenicity through a highly promiscuous dimer interface.Structure. 2010 May 12;18(5):563-70. doi: 10.1016/j.str.2010.02.012. Structure. 2010. PMID: 20462490 Free PMC article.
-
Amyloidosis and POEMS syndrome.Expert Opin Pharmacother. 2010 Jun;11(9):1501-14. doi: 10.1517/14656561003769874. Expert Opin Pharmacother. 2010. PMID: 20426710 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical